Psychedelic Alpha Bulletin 221: Helius phase 2a results, R-MDMA safety target update, and phase 3 plans for 5-MeO-DMT and psilocybin

Helius reports murky phase 2a results in its ongoing psychedelic development program, framing uncertainty around efficacy and study signals. ATAIBEckley claims R-MDMA met a safety goal, with additional discussion of how the SAD program and adverse event profile shaped the update. Phase 3 design receives emphasis for 5-MeO-DMT in treatment resistant depression, alongside a separate phase 3 direction for psilocybin targeting smoking cessation. Overall, the bulletin links early clinical ambiguity and safety milestones to next step trial designs.